Venus Remedies Limited

526953

INE411B01019

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:50 2024-04-19 am EDT			5-day change	1st Jan Change
329 ^INR	-1.70%		+0.08%	-18.96%

Mar. 19	Venus Remedies Secures Marketing Authorizations in Ukraine for Three Oncology Drugs	MT
Mar. 08	Venus Remedies Gets Ukraine's Marketing Approval for Three Oncology Products	MT

Venus Remedies Limited Announces Earnings Results for the First Quarter Ended June 30, 2021

August 12, 2021 at 10:06 am EDT

Venus Remedies Limited announced earnings results for the first quarter ended June 30, 2021. For the first quarter, the company announced total revenue was INR 1,317.65 million compared to INR 1,907.8 million a year ago. Net income was INR 116.97 million compared to INR 19.73 million a year ago. Basic earnings per share from continuing operations was INR 8.86 compared to INR 1.6 a year ago.

Latest news about Venus Remedies Limited

Venus Remedies Secures Marketing Authorizations in Ukraine for Three Oncology Drugs	Mar. 19	MT
Venus Remedies Gets Ukraine's Marketing Approval for Three Oncology Products	Mar. 08	MT
Venus Remedies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Venus Remedies Gets Ukraine Marketing Approval for Chemotherapy Drug, Antibiotics	Feb. 13	MT
Venus Remedies Gets Marketing Authorization in Malta for Two Chemotherapy Drugs	Jan. 12	MT
Venus Remedies Gets Authorization to Market Cancer Drugs in Israel, Colombia	Dec. 21	MT
Indian Equities Clock Sharp Losses on Wednesday Due to Widespread Selling	Dec. 20	MT
Venus Remedies Expands Into Wellness Business	Dec. 20	MT
Venus Remedies Gets Bahrain Marketing Authorization for Enoxaparin	Dec. 18	MT
Indian Equities Score Another Record Highs on Tuesday, Lifted by Ruling Party's State Polls Win	Dec. 05	MT
Venus Remedies Gets Azerbaijan's Marketing Approval for Blood Clot Prevention Drug	Dec. 05	MT
Venus Remedies Gets Marketing Approval for Cancer Drugs in Philippines, Saudi Arabia	Dec. 01	MT
Venus Remedies Limited Receives Market Authorizations in Saudi Arabia and Philippines	Dec. 01	CI
Venus Remedies' Consolidated Profit Jumps in Fiscal Q2	Nov. 27	MT
Venus Remedies Arm Gets Authorization to Market Cancer Drug in UK	23-10-26	MT
Venus Remedies Secures Marketing Approval for Six Key Chemotherapy Drugs in Philippines	23-10-16	MT
Venus Remedies Limited Receives Marketing Approval from the Philippines for Six Key Chemotherapy Drugs	23-10-16	CI
Venus Remedies Launches Antibiotic Elores in Ecuador	23-10-12	MT
Venus Remedies Limited Expands Global Reach with the Launch of Elores in Ecuador	23-10-12	CI
Venus Remedies Gets Marketing Authorization from Serbia for Chemotherapy Drugs	23-09-20	MT
Venus Remedies Limited Extends Its Oncology Portfolio in South Eastern Europe with Serbian Marketing Approval for Gemcitabine and Docetaxel	23-09-20	CI
Venus Remedies Gets Saudi Arabia Marketing Approval for Enoxaparin	23-08-28	MT
Venus Remedies Launches Flagship Drug in Oman	23-08-17	MT
Venus Remedies Launches its R&D Drug Elores, in the $1.4 Billion Pharmaceutical Market in Oman	23-08-17	CI
Venus Remedies Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI

Chart Venus Remedies Limited

Duration

Period

More charts

Company Profile

Venus Remedies Ltd is a research-based pharmaceutical company. The Company is a global injectable manufacturer, possessing a wide product basket catering to therapeutic segments of anti-infective specially in antimicrobial resistance (AMR), oncology, skin and wound care and pain management. The Company operates in the Pharmaceutical Formulation segment. It manufactures products catering to the critical care and super specialty segments. The Company's product portfolio includes formulations such as injectables, tablets, and topical preparations. The Company offers solutions in the domains of antimicrobial resistance (AMR), oncology, skin & wound care, neurology, anticoagulants, pain management, herbal portfolio and disinfectants. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Companyâs brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful and Nervolize. It has three manufacturing facilities.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VENUS REMEDIES LIMITED	-18.96%	53.54M
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B